ライフサイエンスコーパス: arthralgia

1 e limited by grade 2 or 3 rash, fatigue, and arthralgia.

2 s characterized by rash, conjunctivitis, and arthralgia.

3 ome and sirolimus-associated pneumonitis and arthralgia.

4 openia, stomatitis/pharyngitis, myalgia, and arthralgia.

5 eterious side effects, such as bone loss and arthralgia.

6 cluded chills, fever, fatigue, headache, and arthralgia.

7 greater than 1 pound is a valid test for TMJ arthralgia.

8 nate between subjects with and those without arthralgia.

9 PT) of 1 pound for the identification of TMJ arthralgia.

10 epicted effusions identify patients with TMJ arthralgia.

11 eactions, fever, chills, abdominal pain, and arthralgia.

12 hyperbilirubinemia, skin rash, myalgia, and arthralgia.

13 ients with chronic unspecified arthritis and arthralgia.

14 n southern Vietnam with fever, headache, and arthralgia.

15 luding fever, headache, chills, myalgia, and arthralgia.

16 ncluded keratoacanthomas, rash, fatigue, and arthralgia.

17 atient cohorts of CHIKV load associated with arthralgia.

18 ver, chills, marked headache, and myalgia or arthralgia.

19 ammatory mediators during alphavirus-induced arthralgia.

20 ood, some develop debilitating and prolonged arthralgia.

21 rus faster and did not experience persistent arthralgia.

22 se or as a rheumatic symptom such as diffuse arthralgia.

23 had a lower overall incidence of chills and arthralgias.

24 ar symptoms, uveitis, auditory symptoms, and arthralgias.

25 a (14%), diarrhea (12%), pruritus (12%), and arthralgia (10%).

26 ]), liver function abnormalities (165 [5%]), arthralgia (106 [3%]), and fatigue (93 [3%]).

27 The most common adverse events were arthralgia (12 [11%] patients in the placebo group and 2

28 ts of all grades included rash (1592 [49%]), arthralgia (1259 [39%]), fatigue (1093 [34%]), photosens

29 e pyrexia (19%), rash (17%), pain (13%), and arthralgia (13%).

30 2411 in the continuous letrozole group) and arthralgia (136 [6%] vs 151 [6%]).

31 cidences of AEs of interest (days 1-42) were arthralgia (17.1% combined lots, 20.4% high-dose, 3.0% p

32 ]), constipation (23 [13%] vs 25 [13%]), and arthralgia (18 [10%] vs 30 [16%]).

33 Crohn's disease (35 [29%] of 122 patients), arthralgia (19 [16%]), and nasopharyngitis (18 [15%]) in

34 ith administration (1/12), delayed transient arthralgia (2/12), and mild marrow suppression (calculat

35 difficulty sleeping (1.9, 1.3-2.8; p=0.001), arthralgias (2.0, 1.1-3.6; p=0.020), and various constit

36 hypercalcaemia (two [<1%] vs 22 [10%]), and arthralgia (22 [10%] vs 13 [6%]).

37 igue (91%), fever (82%), headache (59%), and arthralgia (29%); onset clustered during 2 distinct peri

38 iarrhea (11%), nausea/vomiting (5%), myalgia/arthralgia (3%), and sensory neuropathy (3%).

39 ported for letrozole versus anastrozole were arthralgia (3.9% v 3.3%, and 48.2% v 47.9% for all adver

40 The most common AEs were arthralgia (33%), hyperkeratosis (27%), and pyrexia (24%

41 The most common adverse events were arthralgia (38 [17%] in the fulvestrant group vs 24 [10%

42 %] vs 3 [4%]), back pain (4 [5%] vs 3 [4%]), arthralgia (4 [5%] vs 1 [1%]), and nausea and vomiting (

43 st common adverse events were fatigue (50%), arthralgias (53%), and hot flashes (59%).

44 ined from a patient with chronic myalgia and arthralgia 6 months after acute SINV infection and asses

45 s included exanthema (88%), fever (76%), and arthralgia (72%).

46 such symptoms as fever (94%) and myalgia or arthralgia (78%).

47 upper respiratory tract infection (8%), and arthralgia (8%).

48 and the apheresis process included myalgias/arthralgias (83%), headache (44%), fever (27%), and chil

49 ncer survivors receiving an AI and reporting arthralgia, a yearlong randomized trial of the impact of

50 (fever/chills, nausea/vomiting, and myalgias/arthralgias), acute infusion-related events (hypotension

51 CHIKV may cause long-lasting arthralgia after acute infection.

52 Mechanisms underlying alphavirus-induced arthralgia and arthritis are not clearly understood, tho

53 iated with outbreaks of acute and persistent arthralgia and arthritis in humans.

54 Joint symptoms (eg, arthralgia and arthritis) are a well-known side-effect o

55 eumatologic conditions owing to non-specific arthralgia and back pain.

56 Patients experienced fever, skin rash, arthralgia and conjunctivitis.

57 Both the arthralgia and fever did not relapse, and anti-ds DNA an

58 On admission, the arthralgia and fever spontaneously resolved, and there w

59 ecological problems and vascular events, but arthralgia and fractures were increased.

60 d; however, there was increased incidence of arthralgia and joint stiffness without significant incre

61 to cause explosive outbreaks of debilitating arthralgia and myalgia in human populations.

62 e 3 stomatitis and fatigue and one developed arthralgia and myalgia.

63 e rash and arthritis and sometimes prolonged arthralgia and myalgia.

64 The main adverse events were arthralgia and other aromatase-inhibitor related symptom

65 nfection (22%), peripheral neuropathy (17%), arthralgia and pain (17%), stomatitis (12%), fatigue (10

66 ack adequate specificity for identifying TMJ arthralgia and were not associated with pain.

67 se events compared with placebo, except that arthralgias and chest pain were worse in those receiving

68 uropathy (n = 6), transaminitis (n = 1), and arthralgias and fatigue (n = 2).

69 of grade 2 constitutional symptoms (myalgias/arthralgias and fatigue) at 75 micrograms/kg, dose escal

70 Grade III myalgias/arthralgias and headaches required dose reduction of SAF

71 Arthralgias and myalgia were reported significantly more

72 ioids were required for treatment-associated arthralgias and/or myalgias during 17 of 52 treatment co

73 lated to nerve pathology as opposed to being arthralgias and/or myalgias.

74 ation between MRI-depicted effusions and TMJ arthralgia, and (2) a PPT of 1 pound does not discrimina

75 lgia only, 157 with both myofascial pain and arthralgia, and 195 controls without TMD pain met criter

76 , including urticarial rash, fever episodes, arthralgia, and bone and muscle pain with cryopyrin-asso

77 itzler syndrome with urticarial rash, fever, arthralgia, and bone pain; 47% reported weight loss, 40%

78 Rash, fever, arthralgia, and conjunctivitis were common symptoms.

79 miting illness characterised by fever, rash, arthralgia, and conjunctivitis.

80 lipidemia, neutropenia, fatigue, leukopenia, arthralgia, and diarrhea were more frequent in the bexar

81 ly mild, systemic reactions (abdominal pain, arthralgia, and diarrhea).

82 a patient with a history of recurrent fever, arthralgia, and disseminated skin lesions.

83 isease, clinical sequelae including uveitis, arthralgia, and fatigue are common and necessitate syste

84 characterised by recurrent episodes of rash, arthralgia, and fever after cold exposure.

85 ammatory disorders that cause rashes, fever, arthralgia, and in some subjects, AA amyloidosis, and ha

86 ly less grade >/= 3 neuropathy, neutropenia, arthralgia, and myalgia occurred in the nab-PC arm, and

87 n with combination therapy, whereas myalgia, arthralgia, and neutropenic fever/sepsis were more commo

88 3 hypertriglyceridemia, two grade 3 myalgia/arthralgia, and one grade 3 fatigue.

89 ropathy, myalgia, nausea, fatigue, headache, arthralgia, and vomiting.

90 h travel to Haiti who developed fever, rash, arthralgias, and conjunctivitis.

91 s fever, chills, headache, malaise, fatigue, arthralgias, and myalgias) before randomization.

92 and warmth) and systemic reactions (chills, arthralgias, and myalgias) in the vaccine group than in

93 eroids who presented with urinary retention, arthralgias, and peripheral edema, subsequently develope

94 6]), hypertension, obstructive lung disease, arthralgias, and peripheral neuropathy.

95 logic toxicities, including nausea, fatigue, arthralgias, and peripheral sensory neuropathy, were mil

96 reactogenicity (local pain/soreness, chills, arthralgia, anorexia, and malaise).

97 hikungunya virus (CHIKV) is a mosquito-borne arthralgia arbovirus that is reemergent in sub-Saharan A

98 c disease phase, which may include long-term arthralgia, arthritis, fatigue, and depression.

99 eatures of this syndrome are malar eruption, arthralgias, arthritis, and laboratory abnormalities inc

100 commonly affected organs, patients may have arthralgias, arthritis, oesophageal disease, or cardiopu

101 Manifestations of SLE such as fatigue, arthralgia/arthritis, and serositis responded particular

102 Joint symptoms were defined as any report of arthralgia, arthrosis, arthritis, or joint disorder on a

103 dy that associated levels of CHIKV load with arthralgia as an indicator of acute CHIKV infection.

104 y identified recent fever, night sweats, and arthralgias as symptoms that may be predictive of recent

105 Arthralgia-associated alphaviruses, including chikunguny

106 dbis-group alphavirus closely related to the arthralgia-associated Ockelbo and Girdwood S.A viruses.

107 (22.5%), headache by 9 mothers (22.5%), and arthralgia by 8 mothers (20.0%).

108 more likely to experience soft tissue edema, arthralgias, carpal tunnel syndrome, and gynecomastia an

109 human patient with psoriasiform dermatitis, arthralgias, congenital cataracts, microcephaly, and dev

110 ic descending macular or maculopapular rash, arthralgias, conjunctival injection, and headache; 27% h

111 Each subject had fever, rashes, arthralgia, conjunctivitis, sensorineural deafness, and

112 by intermittent episodes of rash with fever, arthralgias, conjunctivitis, and leukocytosis.

113 Nausea, arthralgia, cough, dyspnea, neutropenia, and anemia were

114 Grade 4 toxicities were arthralgia, diarrhea, and vomiting.

115 ce as high as that in the placebo group were arthralgia, diarrhea, pruritus, vomiting, and chest pain

116 Grade 3 rash and arthralgia each were reported in 1 romiplostim-treated p

117 More myalgia, arthralgia, edema, and febrile neutropenia occurred on t

118 Children reported fewer arthralgia events than adults (one [<1%] of 303 children

119 The most frequent toxicities were myalgia/arthralgia, fatigue, and triglyceridemia.

120 o those observed in other tumor cohorts (eg, arthralgia, fatigue, myalgia, and nausea), and included

121 Fever, myalgias/arthralgias, fatigue, nausea, and headaches were the mos

122 racterized by intermittent episodes of rash, arthralgia, fever and conjunctivitis after generalized e

123 fatigue (six [24%]), nausea (six [24%]), and arthralgia (five [20%]).

124 tial (> 50%) and sustained improvement in AI arthralgia for both O3-FAs and placebo but found no mean

125 ds increased the sensitivity for identifying arthralgia from 22% to 100%, with a corresponding decrea

126 of clinical presentations of joint-specific arthralgia from this CHIKV cohort.

127 evolocumab-treated patients were back pain, arthralgia, headache, muscle spasms, and pain in extremi

128 onset of signs and symptoms including rash, arthralgia, headache, pruritus, myalgia, and fever.

129 utable to malaria, with fatigue, myalgias or arthralgias, headache, and chills most commonly reported

130 ded peripheral neuropathy in 57%, myalgia or arthralgia in 30%, neutropenia in 53%, neutropenic fever

131 inical trials; however, it induced transient arthralgia in 8% of the vaccinees.

132 pidemics of severe, persistent, debilitating arthralgia in Africa and Asia.

133 HIKV infection and also show that persistent arthralgia in humans may be caused by persistent CHIKV i

134 emonstrate that alphaviruses associated with arthralgia in humans replicate within bone-associated co

135 itoes and causes febrile illness with severe arthralgia in humans.

136 to-borne alphavirus that causes debilitating arthralgia in humans.

137 virus that causes chronic and incapacitating arthralgia in humans.

138 Exercise led to improvement in AI-induced arthralgia in previously inactive breast cancer survivor

139 ined whether acupuncture improves AI-induced arthralgias in women with early-stage BC.

140 en, symptoms included transient arthritis or arthralgias (<6 weeks duration) in 4 women, arthralgia o

141 uded rash, neutropenia, fatigue, neuropathy, arthralgia, myalgia, and diarrhea.

142 y is patients with symptoms of fibromyalgia (arthralgia, myalgia, fatigue) and oral and ocular drynes

143 Other patients develop a syndrome of diffuse arthralgia, myalgia, fatigue, and subjective cognitive d

144 eurological symptoms (extremity paresthesia, arthralgia, myalgia, malaise, pruritus, headache, dizzin

145 e low-grade fever, headache, neck stiffness, arthralgia, myalgia, or fatigue.

146 ed by attacks of fever, sterile peritonitis, arthralgia, myalgia, skin rash, and/or conjunctivitis; s

147 edema and neuropathy, are uncommon, and the arthralgia/myalgia syndrome was not observed.

148 included nausea and emesis, neuropathy, and arthralgia/myalgia.

149 s were most commonly either musculoskeletal (arthralgias, myalgias, and weakness) or pulmonary (cough

150 f fever > 39 degrees C, hypotension, rigors, arthralgias, myalgias, headache, and/or malaise.

151 s, including headache, elevated temperature, arthralgias, myalgias, or fatigue, a larger number of ma

152 most frequent complaints and diagnoses were arthralgia (n = 129 [77.7%]), fatigue (n = 116 [69.8%]),

153 = 1), specified arthritis (n = 11, n = 19), arthralgia (n = 24, n = 7), fibromyalgia (n = 4, n = 11)

154 otein antibody (ACPA)-positive patients with arthralgia (n = 58 serum samples), patients with osteoar

155 Clinical sequelae were common, including arthralgias (n=210, 76%), new ocular symptoms (n=167, 60

156 norexia, asthenia, diarrhea, fever, myalgias/arthralgias, nausea, or vomiting (P < .05) at admission.

157 Fever, myalgia, rash, night sweats, and arthralgia occurred more frequently in patients with pri

158 Arthralgia occurs in up to 50% of breast cancer survivor

159 rent blistering skin lesions, bronchiolitis, arthralgia, ocular inflammation, enterocolitis, absence

160 arthralgias (<6 weeks duration) in 4 women, arthralgia of indeterminate chronicity in 1 woman, and c

161 iduals diagnosed with the myofascial pain or arthralgia of TMJD.

162 Myalgias and arthralgias of grades 1 to 2 occurred in 16 patients and

163 des of fever, skin rash, abdominal pain, and arthralgia, of whom 1 had elevated levels of serum IgD.

164 subjects with myofascial pain only, 20 with arthralgia only, 157 with both myofascial pain and arthr

165 ficant associations were found for the small-arthralgia-only group.

166 purpura (75%), peripheral neuropathy (52%), arthralgia or arthritis (44%), glomerulonephritis (35%),

167 symptoms including recurrent fever attacks, arthralgia or arthritis and fatigue.

168 tly leading to dose reductions were rash and arthralgia or arthritis.

169 n = 11), and multiple symptoms with minimal arthralgia or myalgia (n = 4, n = 14).

170 hibiting the progression of the disease from arthralgia or UA to RA.

171 .16), they were less likely to have myalgias/arthralgias (P< .001) and vomiting (P = .02).

172 nificantly enriched in synovial tissues from arthralgia patients.

173 than that among patients with ACPA-positive arthralgia, patients with OA, and healthy control subjec

174 diarrhea, constipation, headache, weakness, arthralgia, poor response to antimalarial medications, o

175 ditional symptoms of weakness, headache, and arthralgia primarily involving her bilateral hands, wris

176 broad and varies between types but includes arthralgia, purpura, skin ulcers, glomerulonephritis, an

177 this protein kinase inhibitor (PKI) include arthralgia, rash, and fatigue, which are reported in up

178 obin level (n=2); patient refusal (n=2); and arthralgia, rash, and malaise (n=1 each).

179 erse events associated with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or

180 most common adverse events were grade 1 or 2 arthralgia, rash, photosensitivity, fatigue, and alopeci

181 events, most commonly nausea, headache, and arthralgia, resulted in interruption of PrEp.

182 cids (O3-FAs) can be effective in decreasing arthralgia resulting from rheumatologic conditions and r

183 the impact of exercise versus usual care on arthralgia severity.

184 mmatory disease was characterized chiefly by arthralgia, skin rashes, and AA amyloidosis.

185 The toxicities of prinomastat were arthralgia, stiffness, and joint swelling.

186 The most common adverse event reported was arthralgia (stratum I: 94 placebo and 114 anastrozole; s

187 rse events were rare; the most frequent were arthralgia (three in the group assigned to fulvestrant p

188 cause profound epidemics of fever, rash, and arthralgia throughout sub-Saharan Africa, Southeast Asia

189 CONCLUSION Women with AI-induced arthralgias treated with TA had significant improvement

190 from anti-citrullinated protein Ab-positive arthralgia, undifferentiated arthritis (UA), early RA, a

191 The most common AEs included arthralgia, upper respiratory tract infection, headache,

192 ed significantly more stomatitis, myalgia or arthralgia, vomiting, nausea, fatigue, and peripheral ne

193 yndrome with fatigue, headache, myalgia, and arthralgia was highly associated with seropositivity (pr

194 However, significant persistent arthralgia was observed in patients with low viremia who

195 Myofascial pain with arthralgia was significantly associated with trauma (OR

196 Mild arthralgia was the most common persistent symptom.

197 tus was associated with clinical complaints (arthralgia, weakness, loss of vitality, and being diabet

198 e was characterized by higher proportions of arthralgia, weakness, myalgia, and age 41-60 years.

199 and specificity of effusions for identifying arthralgia were 85% and 28%, respectively.

200 ith arm 1, although grade 2/3 neuropathy and arthralgia were less common.

201 men taking GH + testosterone (32% vs 0%) and arthralgias were more common in men taking GH (41% vs 0%

202 Reversible grade 2 fatigue and myalgias/arthralgias were seen in all pts at 75 micrograms/kg.

203 s, such as cheilitis, headache, and myalgias/arthralgias, were mild or absent.

204 eeks to months of debilitating polyarthritis/arthralgia, which is often poorly managed with current t

205 on was used to compare those with AI-related arthralgia with those who did not report symptoms, adjus

206 toms, including cutaneous rash, myalgia, and arthralgia, with the latter sometimes persisting for mon

207 atients with FCAS developed rash, fever, and arthralgias within 1-4 h.